| [1] |
Cui X, Zhang X, Liu M, et al. A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors[J]. Genomics, 2020, 112(6): 3958-3967.
|
| [2] |
Ihle NT, Abraham RT. The Pten-Parkin axis: at the nexus of cancer and neurodegeneration[J]. Molecular Cell, 2017, 65(6): 959-960.
|
| [3] |
Poulogiannis G, McIntyre RE, Dimitriadi M, et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice[J]. Proc Natl Acad Sci USA, 2010, 107(34): 15145-15150.
|
| [4] |
Xiong D, Wang Y, Kupert E, et al. A recurrent mutation in PARK2 is associated with familial lung cancer[J]. Am J Hum Genet, 2015, 96(2): 301-308.
|
| [5] |
Li C, Zhang Y, Cheng X, et al. PINK1 and PARK2 suppress pancreatic tumorigenesis through control of mitochondrial iron-mediated immunometabolism[J]. Dev Cell, 2018, 46(4): 441-455.e8.
|
| [6] |
Lin DC, Xu L, Chen Y, et al. Genomic and functional analysis of the E3 ligase PARK2 in glioma[J]. Cancer Res, 2015, 75(9): 1815-1827.
|
| [7] |
Zhang ZL, Wang NN, Ma QL, et al. Somatic and germline mutations in the tumor suppressor gene PARK2 impair PINK1/Parkin-mediated mitophagy in lung cancer cells[J]. Acta Pharmacol Sin, 2020, 41(1): 93-100.
|
| [8] |
Zhou X, Li Y, Wang W, et al. Regulation of Hippo/YAP signaling and esophageal squamous carcinoma progression by an E3 ubiquitin ligase PARK2[J]. Theranostics, 2020, 10(21): 9443-9457.
|
| [9] |
Lei Z, Duan H, Zhao T, et al. PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway[J]. Cell Death Dis, 2018, 9(3): 375.
|
| [10] |
Duan H, Lei Z, Xu F, et al. PARK2 suppresses proliferation and tumorigenicity in non-small cell lung cancer[J]. Front Oncol, 2019, 9: 790.
|
| [11] |
Chen H, Li Y, Li Y, et al. PARK2 promotes mitochondrial pathway of apoptosis and antimicrotubule drugs chemosensitivity via degradation of phospho-BCL-2[J]. Theranostics, 2020, 10(22): 9984-10000.
|
| [12] |
Xu L, Lin DC, Yin D, et al. An emerging role of PARK2 in cancer[J]. J Mol Med (Berl), 2014, 92(1): 31-42.
|
| [13] |
Sun X, Liu M, Hao J, et al. Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation[J]. Cell Cycle, 2013, 12(7): 1133-1141.
|
| [14] |
Editorial expression of concern: parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27[J]. Proc Natl Acad Sci USA, 2017, 114(16): E3364.
|
| [15] |
Ikeuchi K, Marusawa H, Fujiwara M, et al. Attenuation of proteolysis-mediated cyclin e regulation by alternatively spliced parkin in human colorectal cancers[J]. Int J Cancer, 2009, 125(9): 2029-2035.
|
| [16] |
Agirre X, Román-Gómez J, Vázquez I, et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia[J]. Int J Cancer, 2006, 118(8): 1945-1953.
|
| [17] |
Denison SR, Wang F, Becker NA, et al. Alterations in the common fragile site gene parkin in ovarian and other cancers[J]. Oncogene, 2003, 22(51): 8370-8378.
|
| [18] |
Denison SR, Callahan G, Becker NA, et al. Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer[J]. Genes Chromosomes Cancer, 2003, 38(1): 40-52.
|